CAS: 52-76-6; (8R,9S,10R,13S,14S,17R)-17-Ethynyl-13-Methyl-2,3,6,7,8,9,10,11,12,13,14,15,16,17-Tetradecahydro-1H-Cyclopenta[a]Phenanthren-17-Ol

上下游产品

CAS号68-22-4 炔诺酮 | CAS号7440-44-0 活性炭 | CAS号3646-28-4 雌甾-4-烯-17-酮 | CAS号3646-30-8 雌甾-4-烯-17-醇 | CAS号51724-44-8 6β-羟基炔诺酮 | CAS号1236-00-6 10β-羟基炔诺酮

雌甾-4-烯-17-醇置于chromium(Vi) Oxide,硫酸,异丙醇,丙酮体系中,化学反应生成 利奈孕醇
参考文献:De Winter Et Al.,Chemistry And Industry,1959,P. 905
标题:De Winter Et Al.,Chemistry And Industry,1959,P. 905

专利信息

专利号:US-8017776-B2
优先权日:2003-07-15
标题 :Methods for synthesis of acyloxyalkyl compounds
发明人：BHAT LAXMINARAYAN; GALLOP MARK A
权利人:XENOPORT INC
摘要:Disclosed herein are methods for synthesizing 1-(acyloxy)-alkyl prodrug derivatives of drugs through oxidation of 1-acyl-alkyl derivatives of drugs under anhydrous reaction conditions. The methods typically proceed stereospecifically, in high yield, do not require the use of activated intermediates and/or toxic compounds and are readily amenable to scale-up.

专利号:US-8143437-B2
优先权日:2002-02-19
标题:Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
发明人：GALLOP MARK A; XIANG JIA-NING; YAO FENMEI; BHAT LAXMINARAYAN; ZHOU CINDY X
权利人:GALLOP MARK A; XIANG JIA-NING; YAO FENMEI; BHAT LAXMINARAYAN; ZHOU CINDY X; XENOPORT INC
摘要:The present invention provides a method for synthesizing 1-(acyloxy)-alkyl derivatives from 1-acyl-alkyl derivatives, which typically proceeds stereospecifically, in high yield, does not require the use of activated intermediates and/or toxic compounds and is readily amendable to scale-up. The current invention also provides 1-acyl-alkyl derivatives of known drug components and methods for synthesizing these 1-acyl-alkyl derivatives.

专利号:US-7667056-B2
优先权日:2002-08-02
标 题 :Process and new intermediates for the preparation of steroids with a progestogen activity
发明人：GRISENTI PARIDE; PECORA FABIO; VERZA ELISA; LEONI MASSIMO; BOSSI LAURA
权利人:POLI IND CHIMICA SPA
摘要:The present invention relates to a new process of synthesis and to some new intermediates for the preparation of steroids with progestogen activity, more particularly, for the preparation of Desogestrel of formula (I). Said process is characterized by the regioselective reduction of the compound of formula (II) to give the intermediate of formula (III).

专利号:US-6225298-B1
优先权日:1994-11-22
标 题 :Compositions and methods for contraception and for treatment of benign gynecological disorders
发明人：SPICER DARCY V; PIKE MALCOLM CECIL; DANIELS JOHN R
权利人:BALANCE PHARMACEUTICALS INC
摘要:Compositions and methods for use in preventing conception or treating benign gynecological disorders, wherein an effective amount of an antiprogestational agent [e.g., progesterone (progestin, progestogen, gestagen) antagonist or progesterone synthesis inhibitor] administered over a first period of time is combined with an effective amount of a progestogen for a second period of time. The antiprogestational agent is selected from single agents or mixtures thereof. The progestogen is selected from single agents or mixtures of natural or synthetic progestogens. The formulations are effective as contraceptive agents and for treatment of benign gynecological disorders including uterine fibroids, premenstrual syndrome, dysfunctional uterine bleeding, polycystic ovarian syndrome and endometriosis.

专利号:US-2005239725-A1
优先权日:2002-02-19
标题:Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof

专利号:US-2001016578-A1
优先权日:1997-06-18
标 题 :Compositions and methods for contraception and for treatment of benign gynecological disorders
发明人：SPICER DARCY V; PIKE MALCOLM CECIL; DANIELS JOHN R
权利人:BALANCE PHARMACEUTICALS INC
摘要:Compositions and methods for use in preventing conception or treating benign gynecological disorders, wherein an effective amount of an antiprogestational agent [e.g., progesterone (progestin, progestogen, gestagen) antagonist or progesterone synthesis inhibitor] administered over a first period of time is combined with an effective amount of a progestogen for a second period of time. The antiprogestational agent is selected from single agents or mixtures thereof. The progestogen is selected from single agents or mixtures of natural or synthetic progestogens. The formulations are effective as contraceptive agents and for treatment of benign gynecological disorders including uterine fibroids, premenstrual syndrome, dysfunctional uterine bleeding, polycystic ovarian syndrome and endometriosis.